Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Trial Profile

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Cyclophosphamide; Cyclophosphamide; Dexamethasone; Dexamethasone
  • Indications Amyloid light-chain amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ANDROMEDA
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Jun 2018 Safety run-in results (n=15) presented at the 23rd Congress of the European Haematology Association
    • 05 Jun 2018 Results (n=15) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top